Onco Wiki / Krankheit

Myelodysplastische Syndrome — Unterrisiko (IPSS-R sehr niedrig / niedrig / mittel)

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDDIS-MDS-LR
ArtErkrankung
Aliase
LR-MDSRisikominderwert für MDSMDS-LRMyelodysplastische Syndrome — geringeres RisikoМДС низького ризикуМієлодиспластичні синдроми, низький ризик (IPSS-R дуже низький / низький / проміжний)
Statusreviewed 2026-04-25 | pending_clinical_signoff
ErkrankungenNone declared
QuellenSRC-ESMO-MDS-2021 SRC-IPSS-M-BERNARD-2022 SRC-NCCN-AML-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Quelle: YAML

icd_o_3_morphology9989/3
icd_o_3_topography["C42.1"]
icd_10D46.9
who_classificationMyelodysplastic neoplasms (per WHO 5th ed.) — lower-risk subgroup by IPSS-R / IPSS-M

Fähigkeiten

Anmerkungen

Risk-stratified archetype split into TWO entities (DIS-MDS-LR and DIS-MDS-HR) because therapeutic intent is fundamentally different: cytopenia management vs disease modification + transplant. IPSS-R remains most widely used; IPSS-M (2022) integrates molecular features and reclassifies ~46%. del(5q) carries unique lenalidomide indication. RS-MDS (SF3B1+) is the luspatercept population. STUB — requires clinical co-lead signoff before publication. Myeloid expansion (heme).

Verwendet von

Therapeutische Relevanz

Algorithmen

Erkrankung

Anwendungsgebiet

Fragebogen

Warnhinweis

Quellen